Skip to main content
. Author manuscript; available in PMC: 2011 Jan 15.
Published in final edited form as: J Immunol. 2009 Dec 4;184(2):746–756. doi: 10.4049/jimmunol.0902962

Figure 6.

Figure 6

CEP-1347 elicits a neuroprotective effect in HIVE mice. Tissue sections from HIVE mice were stained for MAP-2 (pink) and NeuN (brown) (A, B, C). Neuronal integrity was assessed in areas of focal encephalitis in CEP-1347 treated mice. A, Immunohistochemical stain for MAP-2 and NeuN in control sham-operated mice. B, Immunohistological image of HIV-1-infected murine brain stained for MAP-2 and NeuN, 7 days post injection. C, Immunohistological image of the brain from an HIV-1-infected mouse treated with 15 mg/kg/d of CEP-1347, stained for MAP-2 and NeuN, 7 days post injection. Original magnification 200×. D, Quantitation of MAP-2 immunoreactivity with increasing doses of CEP-1347. Values are mean ± SEM from multiple images obtained at original magnification 200× per mouse (4 mice/group). E, Quantitation of NeuN immunoreactivity with increasing doses of CEP-1347. Values are mean ± SEM from multiple images per mouse (4 mice/group).